214 related articles for article (PubMed ID: 37235573)
1. Liquid biopsy-based monitoring of residual disease in multiple myeloma by analysis of the rearranged immunoglobulin genes-A feasibility study.
Marx A; Osváth M; Szikora B; Pipek O; Csabai I; Nagy Á; Bödör C; Matula Z; Nagy G; Bors A; Uher F; Mikala G; Vályi-Nagy I; Kacskovics I
PLoS One; 2023; 18(5):e0285696. PubMed ID: 37235573
[TBL] [Abstract][Full Text] [Related]
2. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
[TBL] [Abstract][Full Text] [Related]
3. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
4. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.
Drandi D; Ferrero S; Ladetto M
Methods Mol Biol; 2018; 1768():229-256. PubMed ID: 29717447
[TBL] [Abstract][Full Text] [Related]
5. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
[TBL] [Abstract][Full Text] [Related]
6. Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients.
Sedlarikova L; Kubiczkova L; Kryukov F; Pelcova J; Adam Z; Pour L; Hajek R; Sevcikova S
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Dec; 159(4):554-61. PubMed ID: 24993743
[TBL] [Abstract][Full Text] [Related]
7. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
[TBL] [Abstract][Full Text] [Related]
8. Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma.
Langerhorst P; Brinkman AB; VanDuijn MM; Wessels HJCT; Groenen PJTA; Joosten I; van Gool AJ; Gloerich J; Scheijen B; Jacobs JFM
Clin Chem; 2021 Jun; 67(6):867-875. PubMed ID: 33709101
[TBL] [Abstract][Full Text] [Related]
9. Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.
Takamatsu H; Ogawa Y; Kobayashi N; Obata K; Narisawa T; Nakayama K; Munemoto S; Aoki G; Ohata K; Kumano Y; Ozaki J; Murata R; Kondo Y; Terasaki Y; Kurokawa T; Miyamoto T; Shimizu N; Fukushima T; Yoshida A; Ueda T; Yoshida T; Nakao S
Exp Hematol; 2013 Oct; 41(10):894-902. PubMed ID: 23727584
[TBL] [Abstract][Full Text] [Related]
10. Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.
Rustad EH; Misund K; Bernard E; Coward E; Yellapantula VD; Hultcrantz M; Ho C; Kazandjian D; Korde N; Mailankody S; Keats JJ; Akhlaghi T; Viny AD; Mayman DJ; Carroll K; Patel M; Famulare CA; Op Bruinink DH; Hutt K; Jacobsen A; Huang Y; Miller JE; Maura F; Papaemmanuil E; Waage A; Arcila ME; Landgren O
Am J Hematol; 2019 Dec; 94(12):1364-1373. PubMed ID: 31571261
[TBL] [Abstract][Full Text] [Related]
11. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.
Wu D; Emerson RO; Sherwood A; Loh ML; Angiolillo A; Howie B; Vogt J; Rieder M; Kirsch I; Carlson C; Williamson D; Wood BL; Robins H
Clin Cancer Res; 2014 Sep; 20(17):4540-8. PubMed ID: 24970842
[TBL] [Abstract][Full Text] [Related]
12. Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients.
Ha J; Lee H; Shin S; Cho H; Chung H; Jang JE; Kim SJ; Cheong JW; Lee ST; Kim JS; Choi JR
J Mol Diagn; 2022 Jan; 24(1):48-56. PubMed ID: 34656761
[TBL] [Abstract][Full Text] [Related]
13. Application of self-quenched JH consensus primers for real-time quantitative PCR of IGH gene to minimal residual disease evaluation in multiple myeloma.
Martinez-Lopez J; Martinez-Sanchez P; Garcia-Sanz R; Sarasquete ME; Ayala R; Gonzalez M; Bautista JM; Gonzalez D; San Miguel J; Garcia-Effron G; Lahuerta JJ
J Mol Diagn; 2006 Jul; 8(3):364-70. PubMed ID: 16825510
[TBL] [Abstract][Full Text] [Related]
14. Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry.
Ho C; Syed M; Roshal M; Petrova-Drus K; Moung C; Yao J; Quesada AE; Benhamida J; Vanderbilt C; Liu Y; Zhu M; Yu W; Maciag L; Wang M; Ma Y; Gao Q; Rustad EH; Hultcrantz M; Diamond BT; Zheng-Lin B; Huang Y; Hutt K; Miller JE; Dogan A; Nafa K; Landgren O; Arcila ME
J Mol Diagn; 2021 Feb; 23(2):181-199. PubMed ID: 33217553
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients.
Vrabel D; Sedlarikova L; Besse L; Rihova L; Bezdekova R; Almasi M; Kubaczkova V; Brožová L; Jarkovsky J; Plonkova H; Jelinek T; Sandecka V; Stork M; Pour L; Sevcikova S; Hajek R
Eur J Haematol; 2020 Mar; 104(3):190-197. PubMed ID: 31763708
[TBL] [Abstract][Full Text] [Related]
16. Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma.
Martins CO; Huet S; Yi SS; Ritorto MS; Landgren O; Dogan A; Chapman JR
J Mol Diagn; 2020 Jul; 22(7):901-911. PubMed ID: 32302778
[TBL] [Abstract][Full Text] [Related]
17. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
Bal S; Costa LJ
Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
[TBL] [Abstract][Full Text] [Related]
18. Considerations for monitoring minimal residual disease using immunoglobulin clonality in patients with precursor B-cell lymphoblastic leukemia.
Jo I; Chung NG; Lee S; Kwon A; Kim J; Choi H; Jang W; Kim S; Lee JW; Yoon JH; Cho B; Han K; Kim Y; Kim M
Clin Chim Acta; 2019 Jan; 488():81-89. PubMed ID: 30389459
[TBL] [Abstract][Full Text] [Related]
19. Reproducibility of low-level residual myeloma immunoglobulin detection using ultra-deep sequencing.
Cédile O; Hansen MH; Dahlmann SK; Kristensen TK; Abildgaard N; Nyvold CG
Exp Hematol; 2023; 119-120():14-20. PubMed ID: 36708872
[TBL] [Abstract][Full Text] [Related]
20. The evaluation of minimal residual disease in multiple myeloma by fluorescent molecular beacons in real time PCR of IgH gene rearrangements and correlation with flow cytometry.
Kara IO; Duman BB; Afsar CU
J BUON; 2013; 18(2):442-7. PubMed ID: 23818359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
